<code id='73AD89CD77'></code><style id='73AD89CD77'></style>
    • <acronym id='73AD89CD77'></acronym>
      <center id='73AD89CD77'><center id='73AD89CD77'><tfoot id='73AD89CD77'></tfoot></center><abbr id='73AD89CD77'><dir id='73AD89CD77'><tfoot id='73AD89CD77'></tfoot><noframes id='73AD89CD77'>

    • <optgroup id='73AD89CD77'><strike id='73AD89CD77'><sup id='73AD89CD77'></sup></strike><code id='73AD89CD77'></code></optgroup>
        1. <b id='73AD89CD77'><label id='73AD89CD77'><select id='73AD89CD77'><dt id='73AD89CD77'><span id='73AD89CD77'></span></dt></select></label></b><u id='73AD89CD77'></u>
          <i id='73AD89CD77'><strike id='73AD89CD77'><tt id='73AD89CD77'><pre id='73AD89CD77'></pre></tt></strike></i>

          Home / entertainment / explore

          explore


          explore

          author:leisure time    Page View:155
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In